Perinatal psychiatry addresses the prevention, identification, and treatment of mental health conditions during pregnancy and the postpartum period, recognizing this as a high-risk window for both new-onset and recurrent psychiatric disorders. Approximately 15-20% of women experience clinically significant depression or anxiety perinatally, with substantial implications for maternal wellbeing, obstetric outcomes, and infant development. The 'maternal mental health crisis' has been increasingly recognized as a public health priority, with suicide and accidental overdose representing leading causes of maternal mortality in the first postpartum year in many countries.
Perinatal mood disorders include perinatal depression (formerly postpartum depression, but now recognized as occurring during pregnancy in 50% of cases), perinatal anxiety disorders, postpartum-specific obsessive-compulsive disorder (often with intrusive thoughts about harm to infant), bipolar disorder (high relapse risk perinatally, especially postpartum), and the rare but psychiatric emergency of postpartum psychosis. Postpartum psychosis affects 1-2 per 1000 deliveries with onset typically in first 2 weeks, characterized by rapid mood lability, psychotic symptoms (delusions often involving infant), confusion, and high risk of suicide and infanticide. Risk factors for perinatal mental illness include personal or family history of mood disorder, prior perinatal psychiatric episode, traumatic birth experience, lack of social support, financial stress, intimate partner violence, and unintended pregnancy.
Modern care emphasizes universal screening with validated tools (Edinburgh Postnatal Depression Scale ≥10 indicating need for further evaluation), shared decision-making regarding pharmacotherapy. Most SSRIs (sertraline, escitalopram, citalopram) are considered first-line during pregnancy with relatively favorable safety profiles, though paroxetine is generally avoided due to small increased risk of cardiac defects. SNRIs and bupropion are alternatives. Decisions weigh untreated maternal mental illness risks (preterm birth, low birthweight, impaired bonding) against medication exposure risks. Most antidepressants are compatible with breastfeeding (sertraline preferred). Mood stabilizers require careful consideration: lithium (cardiac defects, primarily Ebstein anomaly), valproate (highest teratogenic risk, contraindicated for women of childbearing age unless absolute necessity), lamotrigine (relatively safe). For postpartum psychosis: immediate psychiatric hospitalization, antipsychotic plus mood stabilizer, ECT for severe cases, with full recovery in most cases. Brexanolone (Zulresso) and zuranolone (Zurzuvae) are newer GABA-A modulators specifically approved for postpartum depression. Integrated care models with obstetric-psychiatric collaboration improve outcomes.